跳至主要内容
临床试验/DRKS00016972
DRKS00016972已完成未知

Contrast-enhanced Ultrasound (CEUS) for determining muscular Perfusion after oral intake of L-Citrulline, L-Arginine, and galloylated epicatechines. - CEUS #Bizeps

niversität Heidelberg, Zentrum für Orthopädie, Unfallchirurgie und Paraplegiologie0 个研究点目标入组 30 人开始时间: 2019年3月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 40 Years(—)
性别
Male

入选标准

  • Young male subjects who workout in athletic sports regularly (e.g. Fitness/Gym, weightlifting, powerlifting)

排除标准

  • Existing contraindications for contrast agent
  • o Known intolerance for SonoVue® or other ultrasound contrast agents
  • o Cardiac Right-to-left shunt
  • o severe heart failure (NYHA III and IV)
  • o uncontrollable hypertension
  • o severe pulmonary hypertension(>90 mmHg)
  • o acute respiratory distress syndrome
  • o taking Dobutamine while suffering cardiovascular instability
  • o severe pulmonary diseases, in particular severe obstructive pulmonary diseases, ARDS.
  • Known diseases of the vascular system, liver, kidneys or gastrointestinal tract
  • Regular consumption of L-Citrulline, L-Arginin, or Vaso6™ within the last 7 days before CEUS-examination
  • Consumption of caffeine or nicotine within the last 12 hours before CEUS-examination
  • physical workout within the last 24 hours before CEUS-examination
  • adults incapable of consent, missing letter of agreement, or rejection of participation

研究者

发起方
niversität Heidelberg, Zentrum für Orthopädie, Unfallchirurgie und Paraplegiologie

相似试验